Koshimizu Toshimasa (JAPIC ) DI DI DI DI DI 10
|
|
|
- ようた かんざとばる
- 9 years ago
- Views:
Transcription
1
2 Koshimizu Toshimasa (JAPIC ) DI DI DI DI DI 10
3 注 DI ISBN p 500
4 (Inoue Shuji) 1 2) ( ) ( ) 1. ( common disease ) 4) 5 10 FDA QOL 3) )BMI 30 BMI 27 ( ) 6,7)
5 HDL- BMI 25 BMI 25 ) 10 2) ( 85cm 90cm ) CT 100cm 2 2) ( ) BMI 30 Pickwick BMI cm ( 2) ( ) 1
6 3 2 ( ) ) Fen-phen 5 6 1
7 3 6) +70% (BMI) mg 1.5 mg 1 (7.1 %) (6.4 %) (4.2 %) (2.1 %) 5 7) MAO 3 Meridia, Reductil Bray 8) mg/ Smith 9) 1 10mg/ 15mg/ 485
8 1 10mg mg 7.3 ( ) ) 4 11) 12) 4 Y
9 4 Y - ciliary neurotrophic factor (Axokine ) 14) 15 16) 4. Xenical FFA 1 120mg A,D,E,K
10 2 300mg 19) 1993 (36.6%) (39.7%) (23.7%) (9.9%) 3.1%) ) mg/ 6 12mg 1 2.5kg UCPs subtype UCP-1 UCP
11 5 10 1) Body mass index, , ) , ) Executive summary of the clinical guidelines on the identification, evaluation,and treatment of overweight and obesity in adults. Arch Intern Med 158:1855, ) Guidance for the clinical evaluation of weight-control drugs, FDAdocuments,No169, ) Connolly HM et al:valvular heart disease associated with fenfluramine phentermine. New Engl J Med 337: , ). 25: , ) Hagiwara M,et al:delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol -A case report Jpn Circ J 64: , ) Bray,GA,et al: Sibutramine produces dose-related weight loss. Obes Res 7: , ) Smith IG: Randomized placebo controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 50: , ) Luque CA,et al:sibutramine:a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother 33: , ) Zhang Y, et al: Positional cloning of the mouse obese gene and its human homologue. Nature 372: , ) Heymsfield SB.et al: Recombinant leptin for weight loss in obese and lean adults: a randomized,controlled,dose-escalation trial. JAMA 282: , ) Madsbad S,et al:improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting Glucagons-like Peptide 1 analog liraglutide(nn2211). Diabetes Care 27: , ) Lambert PD, et al: Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat,without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci USA.98: , ) Simiand J,et al: SR ,a CB1 cannabinoid receptor antagonist, selectively
12 reduces sweet food intake in marmoset. Behav Pharmacol 9: , ) Trillou CR.et al:anti-obesity effect of SR141716,a CB1 receptor antagonist,in dietinduced obese mice. Am J Physiol Regul Integr Comp Physiol 284: R , ) Finer N,et al.:one year treatment of obesity: a randomised, double-blind, placebocontrolled, multicentre study of orlistat(xenicalr), a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 24: , ) Hill JO,et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting. Am J Clin Nutr 69: , ). (NIDDM) BAYg5421(Acarbose) Placebo. 149: , ) -gulucosidase AO : , 1992.
13 10 DB DB CD-ROM , I 100mg 200 g 300mg 5mg 10mg 15mg TEL TEL
14 !! JAPIC CONTENTS!! 16 1 JAPIC Web JAPIC CONTENTS JAPIC CONTENTS 1 Information JAPIC CONTENTS ( ) PDF 1 JAPIC CONTENTS 500 JAPIC JAPIC CONTENTS PDF . [email protected] TEL JAPIC iyakusearch iyakusearch 10 JAPIC TEL
15 5 JAPIC II JAPIC 5 JAPIC JAPIC JAPIC JAPIC 3 3 JAPIC JAPIC iyakusearch JAPIC JAPIC Web iyakusearch EMBASE JAPICDOC JAPIC JAPIC
16 5 JAPIC JAPIC 122 Q A I % 0 25(20.5%) % 1(0.8%) 2. JAPIC % 3. JAPIC % JAPIC JAPICDOC 57 (46.7) 37 (30.3) 2 (1.6) 26 (21.3) JAPICDOC ( 35 (28.7) ) 55 (45.1) 4 (3.3) 28 (22.9) NewPINS 19 (15.5) 56 (45.9) 7 (5.7) 40 (32.8) ADVISE 18 (14.8) 57 (46.7) 7 (5.7) 40 (32.8) SOCIE 17 (13.9) 54 (44.3) 6 (4.9) 45 (36.9) SHOUNIN 8 ( 6.6) 53 (43.4) 12 (9.8) 49 (40.2) MMPLAN 7 (5.7) 60 (49.1) 11 (9.0) 44 (36.1) 85 (69.7) 13 (10.7) 5 (4.1) 19 (15.5) JAPIC NEWS 62 (50.8) 26 (21.3) 1 (0.8) 33 (27.1) JAPIC CONTENTS 59 (48.4) 28 (22.9) 3 (2.5) 32 (26.2) 55 (45.1) 34 (27.9) 2 (1.6) 31 (25.4)
17 45 (36.9) 34 (27.9) 6 (4.9) 37 (30.3) JAPIC 37 (30.3) 44 (36.1) 4 (3.3) 37 (30.3) 33 (27.0) 42 (34.4) 11 (9.0) 36 (29.5) 20 (16.4) 50 (40.9) 6 (4.9) 46 (37.8) Regulations View 18 (14.8) 40 (32.8) 19 (15.5) 45 (36.9) 16 (13.1) 58 (47.5) 5 (4.1) 43 (35.2) JAPIC CONTENTS Web 11 (9.0) 50 (41.0) 13 (10.7) 48 (39.3) JAPIC ( ) 11 (9.0) 51 (41.8) 14 (11.5) 46 (37.7) 52 (42.6) 29 (23.8) 8 (6.6) JAPIC Q 33 (27.0) JAPIC Daily Mail 47 (38.5) 34 (27.9) 9 (7.4) 32 (26.2) 29 (23.8) 48 (39.3) 4 (3.3) 41 (33.6) JAPIC Q Plus 16 (13.1) 45 (36.9) 13 (10.7) 48 (39.3) JAPIC Daily Mail Plus 17 (13.9) 44 (36.1) 13 (10.7) 48 (39.3) PubMed 8 (6.6) 53 (43.4) 11 (9.0) 50 (41.0) SGML PDF 8 (6.6) 53 (43.4) 11 (9.0) 50 (41.0) 4. JAPIC 13 iyakusearch TEL
18 JASDI JAPIC NewPINS JAPICDOC JAPIC NewPINS JAPIC
19 NewPINS 2004/02/26 12,356 7,547 JAPIC 143,757 JAPIC 108, , JAPIC 6, ,035 4 AST(GOT) ALT(GPT) Al-P -GTP JAPIC 76 JAPIC NewPINS JAPICDOC JAPIC MedDRA JART
20 1 JAPIC JAPIC :30 15:00 3 PhaRMA 30 JAPIC TEL ( ) TEL
21
22 9,608 3,874 USAN( )
23 JAPIC IT JAPIC JAPIC iyakusearch 3
24 TEL Regulations View No.107. JAPIC CONTENTS No No JAPIC NEWS No.244. DB FAX No JAPIC-Q. JAPIC-Q Plus. JAPIC Daily Mail No JAPIC Daily Mail Plus No PubMed
25 JIP JIP e-infostream. JAPICDOC JAPICDOC ADVISE MMPLAN 7 9. SOCIE. NewPINS. SHOUNIN <JST JOIS > JAPICDOC 7 TEL
26 JAPIC JAPIC NEWS No ( 1 ) TEL 03(5466)1811 FAX 03(5466)1814
437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
2007050781......_.L.O...z.W
a s d f g a s d f g h j k l 0 in vitro in vivo in vitro in vivo in vivo in vivo in vitro Metabolism Metabolism Endocr Endocr Endocrinol Ann NYA cad Sci J clin Endocr Metab
2001 2003 2005 2006 2007 2008
2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書（案）
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
BAANs理論に基づく保健指導プログラム暫定版
WHO 4 5 10% L- -3 RNA L - 1960-3 RNA mrna Bio Activating Advanced Nutrients BAANs BAANs BAANs BAANs L- (NO) -3 EPA, DHA) RNA RNA DNA TNF- PAI-1 ( ) BAANs 40 50% 20% 1Kg 7,000Kcal 50Kcal 11 50Kcal
The Heart Healthy Tocotrienol Complex Tocomin SupraBio
The Heart Healthy Tocotrienol Complex Tocomin SupraBio The Heart Healthy Tocotrienol Complex Tocomin SupraBio 1. Fact Sheet No. 317; World Health Organization (WHO), 2007 2. LLOYD-JONES D. et al. Circulation
268 LSG 図 Lee ABCD 表 1 4 Age BMI C Duration Still DiaRem 表 1 4 HbA1c Ⅱ 対象と方法 1 17 LSG 6 3 Excess Weight Loss EWL BMI 25 kg/m 2 Hb
52 5 18 1 267 原著 ( 臨床研究 ) LSG ABCD DiaRem LSG 3 93.1 1 7.8 CR37.5 PR33.3 1 ABCD 5 DiaRem 12 LSG ABCD DiaRem LSG 腹腔鏡下スリーブ状胃切除術,ABCD スコア,DiaRem スコア Ⅰ はじめに Bariatric Surgery 2 1 metabolic surgery 2 ABCD 2
1) van Meer, G., Op den Kamp, J. A.: J. Cell. Biochem., 19, 193-2040982) 2) Gaffet, P., Bettache, N., Bienvenue, A.: Biochemistry, 34, 6762-6769(1995) 3) Sims, P. J., Wiedmer, T.: Thromb. Haemost., 86,
Various function and toxicity of iron Key words 1) Hentze, M. W. et al: Cell, 117, 285-297 (2004) 2) Ganz, T.: Blood, 102, 783-788 (2003) 3) Nemeth, E. et al.: Science, 306, 2090-2093 (2004) 4) Hentze,
VOL33NO.3/2010 A B A B p-erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 Erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 p-vasp VASP C D enos/gapdh x-fold vs sham 2.0 1.5 1.0 0.5 * 0 ANP (-) (+) (-)
第124回日本医学会シンポジウム
IV β Therapeutic approaches to obesity HIRONOBU YOSHIMATSU Department of Internal Medicine 1, Faculty of Medicine, Oita University Key words 124 124 1,2 BAT uncoupling protein 1UCP1 1,3 A 1 α-fluoromethylhistidinefmh
JHN Journal Club 手稲渓仁会病院
JHOSPITALIST network GUIDE-IT trial; The Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure multicentre randomised clinical trial 20171010 1 70 (EF 30%), (PCI), (HbA1c
32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
Short Review Hidenori Takagi, Fumio Takaiwa, E-mail : [email protected] 13) Hirahara, K. et al. : J. Allergy Clin. Immunol., 102, 961-967 (1998) 14) Takagi, H. et al.: Proc. Natl. Acad. Sci.
食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
1315 (15)
(14) 1315 (15) 1316 (16) 1317 (17) 1318 (18) 1319 (19) 1320 (20) 1321 (21) 1322 quinidine, disopyramide, and procainamide in isolated atrial myocytes : Mediation by 2) Inoue H, et al: Effects of pentisomide
第124回日本医学会シンポジウム
III γ γ γ α γ Molecular Mechanism of Insulin Resistance by Adipocytes TAKASHI KADOWAKI Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo Key words γ 110 124 TNFα FFA 1,2
; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9
32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5
表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
BMI18 1
The role of nutrition intervention for increasing body weight in college girls with BMI less than 18. Yukiko Miyake BMI18 1 BMI18 1950 2 1/10 2007 1 14 NY DSMIV WHO ICD101992 2 17 20 BMI18.5 22.6 21 21
C/NC : committed/noncommitted
C/NC : committed/noncommitted 110 time post-icd implant 1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report : Effect of encainaide and flecainide on mortality in a
日本皮膚科学会雑誌第122巻第2号
J Dermatol Sci Vitam Horm NEnglJMed Lancet J Clin Invest Antitoxid Redox Signal Diabetes Metab Res Rev Diabetes Care Diabet Med Diabetes care Diabetes Care J Foot Ankle Surg Wound Repair Regen Lancet Foot
胆石症
,. vs 64 .. vs. -, Ransohoff DF, Gracie W. Treatment of gallstones. Ann Intern Med ; 119 : - Halldestam I, Enell EL, Kullman E, et al. Development of symptoms and complications in individuals with asymptomatic
1) Lysozyme and Viral Infections, 2nd Intern- Symposium on Fleming's Lysozyme, ational Milano, Apr. 1961. 2) Ermol'eva, Z.V. et al.: Experimental study and clinical application of lysozyme. Fed. Proc.
1 2 D- D- 1206 D- D- -2003 120 /2004 D-FDA GRAS D D- 3 5 5 D- 75 10g/kg 14 40 20 D-101520 90 1520 20%101520 1520 D- 5(D- 2300-6700mg//) () 2024 615 D- 41220g/kg/ 1220g/kg/ 20g/kg/ 1220g/kg/ () 50 D- 10%
5.3mg () 1 2SD 2 1.5SD 17 15 2 4 4 3 ( ) 瘙 3 嘔 気 嘔 吐 腹 痛 消 化 不 良 便 秘 4 24 p * p ** IGF-I (ng/ml) 77.12±60.19 238.97±143.60 161.85±113.30 [124.08, 199.63] (p
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
WHO Library Cataloguing in Publication Data 2003, Wilkinson,Richard Marmot,Michael Social determinants of health SDH The social gradient Stress Early life Social exclusion Work Unemployment Social support
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
日本皮膚科学会雑誌第121巻第11号
β Clin Rheumatol Arthritis Rheum Am J Cardiol J Rheumatol J Rheumatol Arthritis Rheum Arthritis Rheum Arthritis Rheum Rheumatology Oxford Rheumatology Oxford Br J Dermatol Arch Dermatol Ann Rheum Dis
2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,
24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998
P.37 P.816 P.17 P.1819 contents 1 2
201211 NEW! P.37 P.816 P.17 P.1819 contents 1 2 3 4 5 6 7 8 http://www.tokiomarine-nichido.co.jp/ 1 2 16 3 11 4 1 18 9 10 5 6 11 12 18 9 10 6 7 8 13 1411 12 5 13 14 15 1615 16 21 17 18 0120-071-281 19
164 SDD & SOD SDD E100 mg 80 mg B500 mg 2 E 2 B 48 /59 81 SDD SOD 10 /63 16 RCT RCT 1992 Gastinne 15 ICU 445 SDD E100 mg 80 mg B 10
163 特 集 SDD & SOD SDD(Selective digestive decontamination),sod(selective oropharynx decontamination), 腸内細菌叢, 耐性菌 Ⅰ はじめに SDD Selective digestive decontamination SOD Selective oropharynx decontamination
‹Àfi¡‚¾”O/…_…C…W…F…X…g/01-01
2002 2003 Guidelines for the Diagnosis,Treatment and Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis (JCS 2004) h 1 2 3 1 1 2 2-1 2-2 2-3 2-4 2-5 2-6 2 1 2 2-1 2-2 3 1 2 4 Circulation
日本皮膚科学会第121巻第9号
Appl Nurs Res Wound Repair Regen Int Wound J Adv Skin Wound Care Ostomy Wound Manage Wound Repair Regen Int J Nurs Stud JAdvNurs Visual Dermatology J Adv Nurs Appl Nurs Res Cochrane Database Syst Rev
untitled
COLAK Mehmed 11000 305 305 180 10000 9000 8000 160 140 120 7000 100 6000 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 80 GH IGF-1 GH GH 5 4 3 2 1 0 2 3 4 5
bc0710_010_015.indd
Case Study.01 Case Study.02 30 Case Study.05 Case Study.03 Case Study.04 Case Study.06 Case Study.07 Case Study.08 Case Study.21 Case Study.22 Case Study.24 Case Study.23 Case Study.25 Case Study.26
2 3 Q1 Q3 Q4 Q2
MARCH 2012 vol. 221 3 02 04 CONTENTS 08 10 Concert Report 11 12 NEWS Index 14 CAMPUS Information 15 Information 16 2 3 Q1 Q3 Q4 Q2 4 5 n u m b e r 0 3 6 7 n u m b e r 0 4 8 9 Concert Report Topics 01 Topics
日本皮膚科学会雑誌第120巻第5号
1 2 3 4 5 6 A B 1 2 α β 3 表 1 ClinicalQuestion CQ1 男性型脱毛症にミノキシジルの外用は有用か? (CQ1.1) 男性の男性型脱毛症 (CQ1.2) 女性の男性型脱毛症 CQ2 男性型脱毛症に塩化カルプロニウムの外用は有用か? CQ3 男性型脱毛症に医薬部外品 化粧品の育毛剤の外用は有用か? CQ3.1t- フラバノン CQ3.2 アデノシン CQ3.3
終末期癌患者に対する 輸液治療の是非
3 A B NSAID D Case stories A B NSAID D Case stories A. IASP Task Force on Taxonomy WHO Collaborating Center for Palliative Cancer Care : Looking forward to cancer pain relief for all. CBC Oxford, Oxford,
8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio
7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine
180 140 22
21 180 140 22 23 25 50 1 3 350 140 500cm 600 140 24 25 26 27 28 29 30 31 1/12 8.3 1/15 6.7 10 1/8 12.5 1/20 140 90 75 150 60 150 10 30 15 35 2,000 30 32 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 % 100 50 33.3
4) H. Takayama et al.: J. Med. Chem., 45, 1949 (2002). 5) H. Takayama et al.: J. Am. Chem. Soc., 112, 8635 (2000). 6) H. Takayama et al.: Tetrahedron Lett., 42, 2995 (2001). 9) M. Kitajima et al: Chem.
<82D282A982C1746F95F18D908F57967B95B E696E6464>
1 2 (90cm 70cm 2015) 3 (68cm 28cm 30cm 12kg 2015) (77.5 109.5cm 2015) 4 (22cm 50cm 50cm 4.6kg 2015) (45cm 62.5cm 2015) (47.4cm 62.5cm 2014) 5 (28.5cm 23.5cm) (45cm 62cm 2015) (97cm 107cm 2015) 6 7 8 9
6 12 10661 93100 227213202 222208197 85kg cm 20 64.521 106856142 2 1 4 3 9767 100 35 cm 7747 208198 90kg 23 5828 10661 93100 cm 227213202 10639 61 64.521 85kg 78kg 70kg 61 100 197204.5 cm 15 61
[] 1
![[] 1](/thumbs/42/22960844.jpg "[] 1")
0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2
NAVIGATION MD Consult MD Consult Home home Books Book List page Journals Journal Search page Drugs Drug Look-up:Drug UpdatesDrug Information News This
NAVIGATION...2 BOOKS...4 JOURNALS...5 DRUGS...8 NEWS...8 NEWS...9 CURRENT PRACTICE...10 PATIENT HANDOUTS...11 LEARNING CENTER...12 Search...13 My Folder...14 1 NAVIGATION MD Consult MD Consult Home home
untitled
2008/04/27 1. 1 2 staticdynamics etc 3 Hedberg A, Carlberg EB, Forssberg H, Hadders-Algra M. Development of postural adjustments in sitting position during the first half year of life. Dev Med Child Neurol.
21 1 503604705 MRI CT 1 3 MRIMRS 5 5 5 5 5 6 7 8 17 1 17 2 17 3 17 4 18 5 19 21 1 23 2 1 27 3 2 48 4 3 88 5 105 6 110 7 118 MRS MRS ATP 312CT 65 60 1 2 1 1 1 2 1 2 2 X CT MRS 3 36657269 MRIMRS 1.5TMRSymphony
SBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
PubMedとは
7 1 PubMed 1994 4 1999 4 2004 4 7 PubMed PubMed http://www.ncbi.nlm.nih.gov/pubmed/ http://pubmed.gov National Library of Medicine; NLM PubMed NLM MEDLINE MEDLINE Index Medicus PubMed PubMed 1879 1964
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
Effects of Diet Class on Overweight Middle-aged Women Analysis of Nutritional Intake Pattern YAMAGUCHI Shizue*, MATSUMOTO Tomoko**, MIMURA Kan-ichi***, ASAI Hitoshi****, OKUDA Toyoko***** * O saka Shin-ai
感覚系における人工臓器 ─人工網膜
人工臓器 最近の進歩 Hiroyuki KANDA, Takashi FUJIKADO 1. はじめに 2. 視覚のなり立ち 図 1 10 著者連絡先 565-0871 2-2 E-mail. [email protected] 1 3. 視覚障害 Quality of Life QOL 2 1 1 12 18 1 25.5 2 21.0 3 8.8 1) 1 51 New